NEW YORK, August 5, 2026, 05:09 EDT
- Autonomix ended Tuesday at $19.50, marking a 434.25% rise. The stock was at $12.15 before the market opened on Wednesday, a decline of 37.69%.
- On October 7, 2025, Patent 12,433,670 was issued. The announcement on Tuesday followed 301 days after.
- Warrants with a price of $5.75 apply to 857,462 shares, representing 88.3% of the existing basic share total.
Shares of Autonomix Medical, Inc. NASDAQ:AMIX surged 434% on Tuesday following disclosure of a patent that had been issued ten months prior. The sharp increase in stock price, not the patent’s original award date, altered the company’s financial outlook.
Patent 12,433,670 was granted on October 7, 2025, according to patent databases. The company issued its statement 301 days after that Tuesday.
Autonomix’s annual report dated May 27 stated that the patent family had already been granted in both the United States and Canada. The document listed 75 granted patents and 37 applications awaiting approval.
| Milestone | Date | Verified detail |
|---|---|---|
| Patent approved | Oct. 7, 2025 | Patent 12,433,670 awarded |
| Annual report submitted | May 27, 2026 | Patent family recorded as granted in U.S. and Canada |
| Corporate update | Aug. 4, 2026 | Issuance noted; shares finished up 434.25% |
Chief Executive Brad Hauser described it as a “meaningful expansion of our intellectual property portfolio.” The patent relates to catheter systems designed for detecting and addressing nerves associated with tumors. The statement did not mention any fresh trial data or FDA action. GlobeNewswire
Nasdaq’s regular trading session had ended at the dateline, while premarket hours continued. AMIX last changed hands at $12.15 at 4:59 a.m., registering a decline of 37.7% from its Tuesday closing price. The regular Nasdaq market reopens at 9:30 a.m. EDT.
Trading activity on Tuesday was highly elevated. S&P Global’s data indicated 115.3 million shares changed hands, almost 119 times the basic share count on July 28.
| Session | Close | Daily change | Volume |
|---|---|---|---|
| July 29 | $4.57 | +66.18% | 68.26 million |
| July 30 | $3.59 | -21.44% | 1.25 million |
| July 31 | $3.44 | -4.18% | 0.48 million |
| Aug. 3 | $3.65 | +6.10% | 0.22 million |
| Aug. 4 | $19.50 | +434.25% | 115.25 million |
AMIX advanced 17.8% in the previous calendar week ending July 31. The stock then jumped 327% between July 29 and Tuesday, with the majority of gains occurring in two sessions marked by heavy trading volume.
As of July 28, Autonomix held roughly $5.1 million in cash with 971,043 shares outstanding. Based on Tuesday’s closing price, the company’s basic market capitalization was around $18.94 million. Factoring out the reported cash results in an estimated value of about $13.84 million.
A higher share price could significantly cut dilution from Autonomix’s $1.35 million at-the-market facility. At $19.50, this would use around 76.6% fewer shares compared to the example in the prospectus. Actual sales will be determined by market pricing and could ultimately not happen.
| Initial ATM estimate | Share price | Shares equaling $1.35 million gross | Share of existing total |
|---|---|---|---|
| Example from prospectus | $4.57 | 295,404 | 30.4% |
| Close on Tuesday | $19.50 | 69,231 | 7.1% |
| Premarket Wednesday | $12.15 | 111,111 | 11.4% |
Initial calculations presuppose a single sale price for all shares. Figures do not account for commissions, costs or changes in market conditions.
The surge similarly pushed 857,462 Series D warrants sharply into the money. With a strike price of $5.75, these warrants were $13.75 in-the-money relative to Tuesday’s close. The number of Series D warrants represents 88.3% of the company’s existing basic share count.
| Preliminary capital scenario | Shares in circulation | Total cash from option exercise | Current basic shares as share of overall |
|---|---|---|---|
| Present basic total | 971,043 | — | 100.0% |
| If all Series D warrants are exercised | 1,828,505 | $4.93 million | 53.1% |
A full cash exercise would almost double the number of shares outstanding. Limits on beneficial ownership may slow down the rate of exercises. The warrants are exercisable right away.
Financing is important as liquidity remains constrained. Operating cash outflow for fiscal 2026 totaled $12.3 million. Maintaining this rate, cash on hand as of July 28 would cover about five months of activity. This is an early estimate.
In May, management stated that resources are expected to be sufficient through, but not past, the fourth quarter of 2026. The company projected an additional $25 million to $32 million would be required prior to the initial commercial launch.
Autonomix is still in the development phase as a device manufacturer. Enrollment in an expansion study was halted following varied early results. The company continues to optimize its U.S. catheter for human application. The platform does not yet hold U.S. marketing approval.
The upcoming required disclosure is expected shortly. Autonomix classifies as a non-accelerated filer with a fiscal year ending in March. Under existing SEC regulations, it has 45 days to file its June quarter report, setting the due date at August 14 unless an extension is granted.
Risks: After-hours trading may involve limited liquidity. Patent coverage does not guarantee positive clinical outcomes. Additional share dilution, funding gaps, clinical trial setbacks or Nasdaq-related concerns could halt the rally.
The patent strengthens an already established intellectual-property portfolio. In the near term, Tuesday saw a lower-cost capital window alongside a more significant dilution overhang.
